MedPeerInc Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

MedPeerInc heeft een totaal eigen vermogen van ¥8.4B en een totale schuld van ¥3.4B, wat de schuld-eigenvermogensverhouding op 40.4% brengt. De totale activa en totale passiva bedragen respectievelijk ¥14.4B en ¥6.0B. De EBIT MedPeerInc is ¥1.3B waardoor de rentedekking 101.8 is. Het heeft contanten en kortetermijnbeleggingen van ¥5.5B.

Belangrijke informatie

40.4%

Verhouding schuld/eigen vermogen

JP¥3.39b

Schuld

Rente dekkingsratio	101.8x
Contant	JP¥5.45b
Aandelen	JP¥8.40b
Totaal verplichtingen	JP¥6.03b
Totaal activa	JP¥14.42b

Recente financiële gezondheidsupdates

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Nov 15

Recent updates

Need To Know: Analysts Just Made A Substantial Cut To Their MedPeer,Inc. (TSE:6095) Estimates

Nov 21

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Nov 15

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Sep 04

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

Aug 02

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

May 21

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ¥8.9B ) 6095 } overtreffen de korte termijn passiva ( ¥2.3B ).

Langlopende schulden: De kortetermijnactiva 6095 ( ¥8.9B ) overtreffen de langetermijnschulden ( ¥3.7B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 6095 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 6095 is de afgelopen 5 jaar gestegen van 6.3% naar 40.4%.

Schuldendekking: De schuld van 6095 wordt goed gedekt door de operationele kasstroom ( 37.8% ).

Rentedekking: De rentebetalingen op de schuld van 6095 worden goed gedekt door EBIT ( 101.8 x dekking).

MedPeerInc Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Recent updates

Need To Know: Analysts Just Made A Substantial Cut To Their MedPeer,Inc. (TSE:6095) Estimates

Consensus revenue estimates fall by 18%

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

MedPeer,Inc., Annual General Meeting, Dec 18, 2024

New minor risk - Share price stability

Upcoming dividend of JP¥4.50 per share

Consensus EPS estimates increase by 31%

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Now 21% overvalued after recent price rise

MedPeer,Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Third quarter 2024 earnings released: EPS: JP¥10.59 (vs JP¥1.28 in 3Q 2023)

Investor sentiment deteriorates as stock falls 27%

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

MedPeer,Inc. to Report Q3, 2024 Results on Aug 14, 2024

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

Second quarter 2024 earnings released: JP¥4.15 loss per share (vs JP¥5.02 profit in 2Q 2023)

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022

Now 23% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint